Podocyte dysfunction in atypical haemolytic uraemic syndrome

被引:37
|
作者
Noris, Marina [1 ]
Mele, Caterina [1 ]
Remuzzi, Giuseppe [1 ]
机构
[1] IRCCS Ist Ric Farmacol Mario Negri, Clin Res Ctr Rare Dis Aldo & Cele Dacco, I-24020 Bergamo, Italy
关键词
PROTEIN-KINASE-C; COMPLEMENT FACTOR-H; EXPERIMENTAL MEMBRANOUS NEPHROPATHY; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE-C; THROMBOTIC MICROANGIOPATHY; SIGNAL-TRANSDUCTION; INTRACELLULAR CA2+; ENDOTHELIAL-CELLS; VEGF INHIBITION;
D O I
10.1038/nrneph.2014.250
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Genetic or autoimmune defects that lead to dysregulation of the alternative pathway of complement have been associated with the development of atypical haemolytic uraemic syndrome (aHUS), which is characterized by thrombocytopenia, haemolytic anaemia and acute kidney injury. The relationship between aHUS, podocyte dysfunction and the resultant proteinuria has not been adequately investigated. However, the report of mutations in diacylglycerol kinase epsilon (DGKE) as a cause of recessive infantile aHUS characterized by proteinuria, highlighted podocyte dysfunction as a potential complication of aHUS. DGKE deficiency was originally thought to trigger aHUS through pathogenetic mechanisms distinct from complement dysregulation; however, emerging findings suggest an interplay between DGKE and complement systems. Podocyte dysfunction with nephrodtic-range proteinuria can also occur in forms of aHUS associated with genetic or autoimmune complement dysregulation without evidence of DGKE mutations. Furthermore, proteinuric glomerulonephritides can be complicated by aHUS, possibly as a consequence of podocyte dysfunction inducing endothelial injury and prothrombotic abnormalities.
引用
收藏
页码:245 / 252
页数:8
相关论文
共 50 条
  • [41] Eculizumab: A guide to its use in atypical haemolytic uraemic syndrome
    Keating G.M.
    Drugs & Therapy Perspectives, 2014, 30 (5) : 166 - 172
  • [42] The Spanish atypical haemolytic uraemic syndrome registry: A genetic update
    de Jorge, Elena Goicoechea
    Barricarte, Ruben Martinez
    Tortajada, Agustin
    Montes, Tamara
    Pinto, Sheila
    Garrido, Cyn-Thia Aberrategui
    Lopez-Trascasa, Margarita
    Sanchez-Corral, Pilar
    de Cordoba, Santiago Rodriguez
    MOLECULAR IMMUNOLOGY, 2007, 44 (16) : 3923 - 3923
  • [43] Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab
    Verhave, Jacobien C.
    Wetzels, Jack F. M.
    van de Kar, Nicole C. A. J.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 131 - 141
  • [44] Understanding the renal pathogenesis of diarrhoea associated haemolytic uraemic syndrome: the role of the podocyte
    Keir, Lindsay
    Richards, Anna
    Spooner, Robert
    Welsh, Gavin
    Satchell, Simon
    Coward, Richard
    Saleem, Moin
    PEDIATRIC NEPHROLOGY, 2012, 27 (09) : 1615 - 1616
  • [45] Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab
    Servais, Aude
    Devillard, Nadege
    Fremeaux-Bacchi, Veronique
    Hummel, Aurelie
    Salomon, Laurent
    Contin-Bordes, Cecile
    Gomer, Helene
    Legendre, Christophe
    Delmas, Yahsou
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (12) : 2122 - 2130
  • [46] Anything but typical: recognising postpartum atypical haemolytic uraemic syndrome
    Eslick, R.
    Motum, P.
    Watson, A.
    Hsu, D.
    THROMBOSIS RESEARCH, 2017, 151 : S114 - S114
  • [47] Atypical haemolytic uraemic syndrome and its treatment: A case report
    Khan, Azhar Ali
    Ahraf, Muhammad Usman
    Javaid, Usman
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2021, 71 (05) : 1496 - 1498
  • [48] Haemolytic Uraemic Syndrome
    Kavanagh, David
    Goodship, Tim
    NEPHRON CLINICAL PRACTICE, 2011, 118 (01): : C37 - C42
  • [49] Haemolytic uraemic syndrome
    Robson Wm.L.M.
    Paediatric Drugs, 2000, 2 (4): : 243 - 252
  • [50] Haemolytic uraemic syndrome
    Michael, Mini
    Bagga, Arvind
    Sartain, Sarah E.
    Smith, Richard J. H.
    LANCET, 2022, 400 (10364): : 1722 - 1740